BG505 SOSIP.664 Trimer Stabilization for Broad Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing an HIV-1 vaccine that elicits broad and potent neutralizing antibodies is challenging due to the virus's immune evasion strategies and extreme sequence variability, making it difficult to generate antibodies that recognize conserved, accessible targets on the HIV envelope glycoprotein.
Innovation Solution
The development of a truncated HIV-1 envelope glycoprotein, specifically the BG505 SOSIP.664 trimer, which is stabilized and modified to enhance secretion, cleavage, and trimerization, and includes specific mutations to prevent aggregation and create epitopes recognized by broad neutralizing antibodies like PG9 and PG16, serving as a vaccine candidate and reagent for screening and crystallization studies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the HIV-1 envelope glycoprotein is used as a vaccine immunogen, then it can elicit neutralizing antibodies, but the virus's immune evasion strategies and extreme sequence variability prevent the generation of broad and potent neutralizing antibodies
Solution Approach 1:
The patent applies parameter changes by modifying the HIV-1 envelope glycoprotein sequence to create a stabilized trimeric structure (SOSIP.664) that preserves immunogenicity while reducing variability. Specific mutations (SOSIP) and truncations are introduced to lock the protein in a native-like trimeric conformation, enhancing its ability to elicit broad neutralizing antibodies despite the virus's natural variability
Solution Approach 2:
The patent creates a composite structure by combining multiple gp120 and gp41 subunits into a trimeric complex that mimics the native viral envelope structure. This composite approach allows the immunogen to present conserved epitopes in a stable, reproducible format that can elicit broadly neutralizing antibodies across different HIV-1 strains
2Stability of the object's composition
If the envelope glycoprotein is stabilized and modified to enhance secretion and trimerization, then antigenicity and stability are improved, but the structure becomes more complex with multiple mutations and truncations
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the envelope glycoprotein in a defined trimeric conformation using the SOSIP.664 design before use as an immunogen. The disulfide bonds and truncations are introduced in advance to lock the structure, ensuring consistent antigenicity and reducing the need for further stabilization during storage and formulation
Solution Approach 2:
The patent extracts the essential immunogenic elements of the envelope glycoprotein by creating a truncated version (gp140) that retains the critical gp120-gp41 interface and trimeric structure while removing variable regions and transmembrane domains. This extraction approach maintains stability and antigenicity while simplifying the overall structure
Data Source
Figure 1
Figure 2
Figure 2
AI summary
The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.